Introduction {#section5-1758835920937425}
============

Colorectal cancer (CRC) accounts for 10.2% of all newly-diagnosed cancers and 9.2% of all cancer-related deaths worldwide annually.^[@bibr1-1758835920937425]^ Despite previous advances in treatment options, CRC prognosis has not improved substantially.^[@bibr2-1758835920937425]^ The 5-year survival rate remains approximately at 90% with early diagnosis, whereas it falls to 13% when the diagnosis is delayed.^[@bibr3-1758835920937425]^ The incorporation of effective CRC biomarkers into therapeutic strategies could markedly improve outcomes for patients with CRC.^[@bibr4-1758835920937425]^ Many prognostic and predictive markers, including *RAS* mutational status, *BRAF* mutations and microsatellite instability, have been used to provide implications for the management of CRC. However, these markers require invasive tests and depend on specific laboratory equipment. Therefore, non-invasive, readily-accessible and cost-effective prognostic indexes are urgently needed to predict prognosis and to evaluate the therapeutic effectiveness in clinical practice for patients with CRC.

Previous evidence has shown that chronic inflammation is extensively involved in CRC development and progression.^[@bibr5-1758835920937425]^ Tumor-associated systemic inflammatory responses involve inflammatory cells and a variety of inflammatory mediators.^[@bibr6-1758835920937425]^ A number of studies have focused on peripheral inflammatory cells and calculated ratios as parameters reflecting the status of immune responses in cancer patients.^[@bibr7-1758835920937425]^ These parameters include the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein levels and systemic immune-inflammation index (SII). SII is defined as the platelet count × neutrophil count/lymphocyte count, and can be easily derived from daily laboratory tests. Many studies have investigated the prognostic role of SII in patients with CRC, yet the results were inconsistent.^[@bibr8-1758835920937425][@bibr9-1758835920937425][@bibr10-1758835920937425][@bibr11-1758835920937425][@bibr12-1758835920937425][@bibr13-1758835920937425][@bibr14-1758835920937425][@bibr15-1758835920937425][@bibr16-1758835920937425][@bibr17-1758835920937425][@bibr18-1758835920937425]--[@bibr19-1758835920937425]^ For example, SII was proposed as a significant prognostic factor in several studies,^[@bibr9-1758835920937425],[@bibr13-1758835920937425]^ whereas the correlation between SII and survival outcomes in CRC was not significant in other studies.^[@bibr10-1758835920937425],[@bibr14-1758835920937425],[@bibr17-1758835920937425]^ Therefore, we comprehensively searched for relevant studies in the literature and carried out a quantitative meta-analysis to evaluate the potential of SII as a CRC biomarker.

Materials and methods {#section6-1758835920937425}
=====================

Search strategy {#section7-1758835920937425}
---------------

The current meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.^[@bibr20-1758835920937425]^ We thoroughly searched the PubMed, Web of Science, Embase and Cochrane Library databases for eligible studies published up until 6 April 2020. The following search phrases were used for literature retrieval: (colonic neoplasms OR colorectal neoplasms OR colon cancer OR rectal cancer OR rectal cancers OR rectal tumor OR colorectal cancer OR CRC OR colorectal tumor OR colorectal carcinoma) AND (systemic immune-inflammatory index OR SII OR systemic-immune-inflammation index OR systemic immune-inflammation index). The detailed search strategies for PubMed are shown in the [Supplemental material online](https://journals.sagepub.com/doi/suppl/10.1177/1758835920937425). We also manually examined the references of the included articles to identify potential inclusions. Since the data used in this study were extracted from previously published literature, no patient consent or ethical approval was necessary.

Inclusion and exclusion criteria {#section8-1758835920937425}
--------------------------------

Studies were included, if (1) CRC diagnosis was histopathologically confirmed in patients, (2) hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) of pretreatment SII with survival outcomes including overall survival (OS) and/or progression-free survival (PFS) were reported, or sufficient data were available to calculate them, or the association between SII and clinicopathological features of CRC was reported, (3) a definite cut-off value of pretreatment SII was determined and (4) full-text articles published in English. Following studies were excluded: (1) reviews, editorials, conference abstracts, letters and case reports, (2) duplicate publications, (3) basic research or animal studies and (4) studies without sufficient data.

Data extraction and quality assessment {#section9-1758835920937425}
--------------------------------------

Two investigators (MD and YS) independently extracted data from eligible studies. Any disagreements were resolved *via* discussion with a third investigator (XG). The following information was extracted: name of the first author, year of publication, country of origin, sample size, age of patients, sex distribution, study design, recruitment time, histological type, follow-up, tumor stage, treatment methods, cut-off values of SII, cut-off selection method, survival endpoints and HRs with corresponding 95% CIs. OS and PFS were the primary and secondary endpoints of this meta-analysis, respectively. We evaluated the methodological quality of the included studies using the Newcastle--Ottawa Scale (NOS).^[@bibr21-1758835920937425]^ The NOS is based on patient selection, comparability and outcome of interest. NOS scores range from 0 to 9, and studies with scores higher than 6 are regarded high quality.

Statistical analysis {#section10-1758835920937425}
--------------------

The pooled HRs and 95% CIs were calculated to estimate the association between SII and OS/PFS in CRC. Statistical heterogeneity among studies was evaluated using Cochran's Q test^[@bibr22-1758835920937425]^ and Higgins *I*^2^ statistics.^[@bibr23-1758835920937425]^ If *I*^2^ \> 50% or *p* \< 0.10 (indicating significant heterogeneity among studies), the data were combined using a random-effects model. Otherwise, a fixed-effects model was applied. Subgroup analyses were performed based on geographical region, treatment, Tumor Node Metastasis (TNM) stage, sample size, cut-off value, cut-off selection method and NOS score to identify the sources of heterogeneity. ORs and 95% CIs were computed to assess the association between SII and clinicopathological characteristics of patients with CRC. OR, as the effect size for association between SII and clinicopathological factors, was expressed along with 95% CI. ORs \>1 with 95% CIs that did not overlap with 1 suggested that a high SII increased the trend of that clinical factor, whereas ORs \< 1 with 95% CIs that did not overlap with 1 were indicators of the decreased trend of that clinical factor. Sensitivity analysis was also conducted to evaluate the effect of the individual study data on the HRs of OS and PFS. Potential publication bias was examined using Begg's and Egger's tests. All statistical calculations were performed using Stata version 12.0 (Stata Corporation, College Station. TX, USA). *p* \< 0.05 (two-sided) was considered statistically significant.

Results {#section11-1758835920937425}
=======

Search results and study characteristics {#section12-1758835920937425}
----------------------------------------

A total of 65 records were identified from database searches. Duplicate records were removed to yield 41 studies. After reviewing the titles and abstracts, a further 26 of them were excluded. Subsequently, 15 studies were evaluated by full-text reading, and five of them were discarded for the following reasons: four studies lacked necessary data and one study was a review article. Through an updated literature search, two more eligible studies^[@bibr16-1758835920937425],[@bibr19-1758835920937425]^ were identified. Finally, a total of 12 studies^[@bibr8-1758835920937425][@bibr9-1758835920937425][@bibr10-1758835920937425][@bibr11-1758835920937425][@bibr12-1758835920937425][@bibr13-1758835920937425][@bibr14-1758835920937425][@bibr15-1758835920937425][@bibr16-1758835920937425][@bibr17-1758835920937425][@bibr18-1758835920937425]--[@bibr19-1758835920937425]^ published between 2016 and 2019 were included in our meta-analysis. The literature search flowchart is shown in [Figure 1](#fig1-1758835920937425){ref-type="fig"}. The 12 eligible studies recruited a total of 3919 patients, with the number of patients in individual studies ranging from 95 to 1383. Eleven studies were conducted in China^[@bibr9-1758835920937425][@bibr10-1758835920937425][@bibr11-1758835920937425][@bibr12-1758835920937425][@bibr13-1758835920937425][@bibr14-1758835920937425][@bibr15-1758835920937425][@bibr16-1758835920937425][@bibr17-1758835920937425][@bibr18-1758835920937425]--[@bibr19-1758835920937425]^ and one in Italy.^[@bibr8-1758835920937425]^ Eleven studies included patients with CRC,^[@bibr8-1758835920937425][@bibr9-1758835920937425]--[@bibr10-1758835920937425],[@bibr12-1758835920937425][@bibr13-1758835920937425][@bibr14-1758835920937425][@bibr15-1758835920937425][@bibr16-1758835920937425][@bibr17-1758835920937425][@bibr18-1758835920937425]--[@bibr19-1758835920937425]^ and one study with colon cancer.^[@bibr11-1758835920937425]^ Eleven studies investigated the relationship between SII and OS,^[@bibr8-1758835920937425][@bibr9-1758835920937425][@bibr10-1758835920937425][@bibr11-1758835920937425][@bibr12-1758835920937425][@bibr13-1758835920937425][@bibr14-1758835920937425]--[@bibr15-1758835920937425],[@bibr17-1758835920937425][@bibr18-1758835920937425]--[@bibr19-1758835920937425]^ eight studies reported the association between SII and PFS,^[@bibr8-1758835920937425][@bibr9-1758835920937425]--[@bibr10-1758835920937425],[@bibr13-1758835920937425][@bibr14-1758835920937425][@bibr15-1758835920937425][@bibr16-1758835920937425][@bibr17-1758835920937425]--[@bibr18-1758835920937425]^ and nine studies provided data on the correlation of SII and clinicopathological features in CRC.^[@bibr8-1758835920937425][@bibr9-1758835920937425][@bibr10-1758835920937425][@bibr11-1758835920937425][@bibr12-1758835920937425]--[@bibr13-1758835920937425],[@bibr15-1758835920937425],[@bibr16-1758835920937425],[@bibr18-1758835920937425]^ The cut-off values ranged from 340 to 1505. Eleven studies were retrospective^[@bibr9-1758835920937425][@bibr10-1758835920937425][@bibr11-1758835920937425][@bibr12-1758835920937425][@bibr13-1758835920937425][@bibr14-1758835920937425][@bibr15-1758835920937425][@bibr16-1758835920937425][@bibr17-1758835920937425][@bibr18-1758835920937425]--[@bibr19-1758835920937425]^ and one study was a prospective trial.^[@bibr8-1758835920937425]^ The main characteristics of the 12 included studies are summarized in [Table 1](#table1-1758835920937425){ref-type="table"}. The NOS scores of all studies ranged from 6 to 9, which indicates high quality (NOS scores ⩾6).

![Flow diagram of the study selection process.](10.1177_1758835920937425-fig1){#fig1-1758835920937425}

###### 

Major features of included studies in this meta-analysis.

![](10.1177_1758835920937425-table1)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author         Year   Country   Histology      Study period   Study design    Sample size   Age, years\      Sex\      TNM stage   Treatment                         Cut-off value   Cut-off selection   Follow-up, months   Survival analysis   NOS score
                                                                                              Median (range)   M/F                                                                                                                                 
  -------------- ------ --------- -------------- -------------- --------------- ------------- ---------------- --------- ----------- --------------------------------- --------------- ------------------- ------------------- ------------------- -----------
  **Passardi**   2016   Italy     CRC            2007--2012     Prospective     289           65.5             174/115   I--IV       Chemotherapy+ targeted therapy    730             X-tile software     36 (1--65)          OS, PFS             9

  **Chen**       2017   China     CRC            1994--2010     Retrospective   1383          NA               788/595   I--IV       Surgical resection                340             ROC analysis        NA                  OS, PFS             6

  **Yang**       2017   China     CRC            2009--2015     Retrospective   95            57               58/37     IV          Chemotherapy+ targeted therapy    460.66          Median value        40 (12--72)         OS, PFS             7

  **Tao**        2018   China     Colon cancer   2011--2013     Retrospective   118           60               63/55     I--IV       Surgical resection                667.75          Median value        36                  OS                  8

  **Xie**        2018   China     CRC            2009--2014     Retrospective   240           59 (18--90)      157/83    IV          Surgical resection                649.45          Median value        26.7 (1.1--92.4)    OS                  8

  **Yang**       2018   China     CRC            2010--2015     Retrospective   98            53 (26--83)      59/39     I--IV       Neoadjuvant chemoradiotherapy     437.72          Median value        37 (16.2--93.3)     OS, PFS             7

  **Zhou**       2018   China     CRC            2007--2015     Retrospective   516           16--87           331/185   I--IV       Surgical resection                568.69          ROC analysis        21.7 (2.1--118.7)   OS, PFS             8

  **Jiang**      2019   China     CRC            2010--2017     Retrospective   102           28--75           72/30     IV          Chemotherapy + targeted therapy   660.55          ROC analysis        33.2 (2.6--94.5)    OS, PFS             7

  **Lu**         2019   China     CRC            2010--2017     Retrospective   182           53.5 (15--93)    95/87     I--II       Surgical resection                1505            ROC analysis        NA                  NA                  7

  **Wang**       2019   China     CRC            2002--2016     Retrospective   452           57               289/163   IV          Surgical resection                517             X-tile software     28                  OS, PFS             8

  **Yang**       2019   China     CRC            2009--2015     Retrospective   220           57               133/87    III--IV     Adjuvant chemoradiotherapy        534.94          ROC analysis        23.9 (12--87)       OS, PFS             7

  **Zhang**      2019   China     CRC            2010--2013     Retrospective   224           67 (30--89)      127/97    I--IV       Surgical resection                642.2           Median value        48                  OS                  8
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CRC, colorectal cancer; F, female; M, male; NA, not available; NOS, Newcastle--Ottawa Scale; OS, overall survival; PFS, progression-free survival; ROC, receiver-operating characteristics curve

Prognostic impact of SII on OS in CRC patients {#section13-1758835920937425}
----------------------------------------------

Eleven studies^[@bibr8-1758835920937425][@bibr9-1758835920937425][@bibr10-1758835920937425][@bibr11-1758835920937425][@bibr12-1758835920937425][@bibr13-1758835920937425][@bibr14-1758835920937425]--[@bibr15-1758835920937425],[@bibr17-1758835920937425][@bibr18-1758835920937425]--[@bibr19-1758835920937425]^ provided data from 3737 patients for the OS analysis. A random-effects model was applied due to the significant heterogeneity detected in these data (*I*^2^ = 83.1%, *p* \< 0.001, [Figure 2](#fig2-1758835920937425){ref-type="fig"} and [Table 2](#table2-1758835920937425){ref-type="table"}). Pooled HR from eligible studies was found to be 1.61, with 95% CI = 1.21--2.13 and *p* = 0.001 ([Figure 2](#fig2-1758835920937425){ref-type="fig"} and [Table 2](#table2-1758835920937425){ref-type="table"}), indicating an association between high SII and poor OS in CRC. Subgroup analysis was also conducted based on the geographical region, treatment procedure, TNM stage, sample size, cut-off value, cut-off selection method and NOS score. High SII was found to be consistently correlated with worse OS irrespective of geographical region, sample size, cut-off value, cut-off selection method or NOS score ([Table 2](#table2-1758835920937425){ref-type="table"}).

![Forest plot of the correlation between systemic immune-inflammation index and overall survival in patients with colorectal cancer.\
CI, confidence interval; HR, hazard ratio](10.1177_1758835920937425-fig2){#fig2-1758835920937425}

###### 

Subgroup analysis of pooled HRs and 95% CIs between SII and OS and PFS in colorectal cancer.

![](10.1177_1758835920937425-table2)

  Variables                                No. of studies   No. of patients   Effects model   HR (95% CI)         ***p***   Heterogeneity   
  ---------------------------------------- ---------------- ----------------- --------------- ------------------- --------- --------------- ---------
  **OS**                                                                                                                                    
  Total                                    11               3737              Random          1.61 (1.21--2.13)   0.001     83.1            \<0.001
  Geographical region                                                                                                                       
  China                                    10               3448              Random          1.63 (1.20--2.23)   0.002     83.2            \<0.001
  Italy                                    1                289               −               1.37 (1.03--1.82)   0.030     −               −
  Treatment                                                                                                                                 
  Surgical resection                       6                2933              Random          1.50 (0.93--2.42)   0.097     90.0            \<0.001
  Chemotherapy + targeted therapy          3                486               Fixed           1.42 (1.14--1.76)   0.002     0               0.873
  Neoadjuvant/adjuvant chemoradiotherapy   2                318               Fixed           2.29 (1.66--3.17)   \<0.001   0               0.655
  TNM stage                                                                                                                                 
  I**--**IV                                6                2628              Random          1.61 (0.99--2.61)   0.056     88.1            \<0.001
  III**--**IV                              1                220               −               2.41 (1.63--3.58)   \<0.001   −               −
  IV                                       4                889               Fixed           1.38 (1.15--1.66)   \<0.001   0               0.858
  Sample size                                                                                                                               
  \<230                                    6                857               Random          1.62 (1.16--2.27)   0.005     58.4            0.034
  ⩾230                                     5                2880              Random          1.59 (1.02--2.50)   0.042     91.3            \<0.001
  Cut-off value of SII                                                                                                                      
  \<550                                    5                2248              Random          1.96 (1.27--3.04)   0.002     87.6            \<0.001
  ⩾550                                     6                1489              Fixed           1.37 (1.15--1.63)   \<0.001   24.5            0.250
  Cut-off selection                                                                                                                         
  X-tile software                          2                741               Fixed           1.32 (1.08--1.61)   0.006     0               0.715
  ROC analysis                             4                2221              Random          2.04 (1.31--3.17)   0.002     81.2            0.001
  Median value                             5                775               Fixed           1.45 (1.16--1.80)   0.001     47.7            0.105
  NOS score                                                                                                                                 
  ⩽7                                       6                2122              Random          1.78 (1.17--2.71)   0.007     83.4            \<0.001
  \>7                                      5                1615              Fixed           1.37 (1.17--1.61)   \<0.001   0               0.712
  **PFS**                                                                                                                                   
  Total                                    8                3155              Random          1.74 (1.26--2.39)   0.001     84.8            \<0.001
  Geographical region                                                                                                                       
  China                                    7                2866              Random          1.87 (1.34--2.61)   \<0.001   81.6            \<0.001
  Italy                                    1                289               −               1.16 (0.90--1.50)   0.259     −               −
  Treatment                                                                                                                                 
  Surgical resection                       3                2351              Random          1.80 (0.99--3.29)   0.056     93.4            \<0.001
  Chemotherapy + targeted therapy          3                486               Fixed           1.31 (1.07--1.61)   0.010     13.9            0.313
  Neoadjuvant/adjuvant chemoradiotherapy   2                318               Fixed           2.43 (1.53--3.88)   \<0.001   0               0.888
  TNM stage                                                                                                                                 
  I**--**IV                                4                2286              Random          1.90 (1.13--3.21)   0.016     89.9            \<0.001
  III**--**IV                              1                220               −               2.33 (1.08--5.02)   0.030     −               −
  IV                                       2                649               Fixed           1.34 (1.11--1.61)   0.002     0               0.428
  Sample size                                                                                                                               
  \<230                                    4                515               Fixed           1.85 (1.41--2.43)   \<0.001   0               0.557
  ⩾230                                     4                2640              Random          1.61 (0.98--2.64)   0.061     93.2            \<0.001
  Cut-off value of SII                                                                                                                      
  \<550                                    5                2248              Random          1.94 (1.26--2.99)   0.003     87.4            \<0.001
  ⩾550                                     3                907               Fixed           1.31 (1.06--1.62)   0.013     22.7            0.274
  Cut-off selection                                                                                                                         
  X-tile software                          2                741               Fixed           1.20 (1.01--1.42)   0.034     0               0.726
  ROC analysis                             4                2221              Fixed           2.49 (2.14--2.91)   \<0.001   42.3            0.158
  Median value                             2                193               Fixed           1.86 (1.30--2.68)   0.001     35.4            0.213
  NOS score                                                                                                                                 
  ⩽7                                       5                1898              Fixed           2.43 (2.10--2.82)   \<0.001   46.9            0.110
  \>7                                      3                1257              Fixed           1.23 (1.05--1.45)   0.011     0               0.494

CI, confidence interval; HR, hazard ratio; NOS, Newcastle--Ottawa Scale; OS, overall survival; PFS, progression-free survival; ROC, receiver-operating characteristics curve; SII, systemic immune-inflammation index; TNM, Tumor Node Metastasis.

Prognostic role of SII for PFS in CRC {#section14-1758835920937425}
-------------------------------------

Data for PFS analysis were extracted from eight studies covering 3155 patients.^[@bibr8-1758835920937425][@bibr9-1758835920937425]--[@bibr10-1758835920937425],[@bibr13-1758835920937425][@bibr14-1758835920937425]--[@bibr15-1758835920937425],[@bibr17-1758835920937425],[@bibr18-1758835920937425]^ The combined data showed that an elevated SII indicated a worse PFS in CRC (HR = 1.74, 95% CI = 1.26--2.39, *p* = 0.001) ([Figure 3](#fig3-1758835920937425){ref-type="fig"} and [Table 2](#table2-1758835920937425){ref-type="table"}). There was significant heterogeneity among the studies as well (*I*^2^ = 84.8%, *p* \< 0.001). Therefore, a random-effects model was adopted. High SII was again associated with poor PFS irrespective of TNM stage, cut-off value, cut-off selection and NOS score. Moreover, high SII also predicted poor PFS in Chinese patients (HR = 1.87, 95% CI = 1.34--2.61, *p* \< 0.001), in patients receiving chemo- and targeted therapy (HR = 1.31, 95% CI = 1.07--1.61, *p* = 0.010) and in patients receiving neoadjuvant chemoradiotherapy (HR = 2.43, 95% CI = 1.53--3.88, *p* \< 0.001) ([Table 2](#table2-1758835920937425){ref-type="table"}).

![Forest plot of the correlation between systemic immune-inflammation index and progression-free survival in patients with colorectal cancer.\
CI, confidence interval; HR, hazard ratio](10.1177_1758835920937425-fig3){#fig3-1758835920937425}

Correlation between SII and clinicopathological factors in CRC {#section15-1758835920937425}
--------------------------------------------------------------

Nine studies comprising 2727 patients^[@bibr8-1758835920937425][@bibr9-1758835920937425][@bibr10-1758835920937425][@bibr11-1758835920937425][@bibr12-1758835920937425]--[@bibr13-1758835920937425],[@bibr15-1758835920937425],[@bibr16-1758835920937425],[@bibr18-1758835920937425]^ reported the connection between SII and eight clinicopathological features. The features were as follows: sex (male *versus* female), tumor differentiation (poor *versus* moderate/well-differentiated), tumor location (rectum *versus* colon), distant metastasis (yes *versus* no), Eastern Cooperative Oncology Group Performance Status (ECOG PS) (1--2 *versus* 0), lymph node metastasis (yes *versus* no), age (years) (\>60 *versus* ⩽60) and tumor size (⩾5 cm *versus* \<5 cm) ([Table 3](#table3-1758835920937425){ref-type="table"} and [Figure 4](#fig4-1758835920937425){ref-type="fig"}). The pooled results suggested that a high SII prior to treatment was associated with poor tumor differentiation (OR = 1.60, 95% CI = 1.27--2.02, *p* \< 0.001), presence of distant metastasis (OR = 2.27, 95% CI = 1.10--4.67, *p* = 0.026), ECOG PS of 1--2 (OR = 1.98, 95% CI = 1.39--2.84, *p* \< 0.001) and tumor size ⩾5 cm (OR = 1.49, 95% CI = 1.18--1.88, *p* = 0.001) ([Table 3](#table3-1758835920937425){ref-type="table"} and [Figure 4](#fig4-1758835920937425){ref-type="fig"}). However, the association between high SII and sex (OR = 0.95, 95% CI = 0.80--1.13, *p* = 0.592), tumor location (OR = 0.76, 95% CI = 0.58--1.03, *p* = 0.081), lymph node metastasis (OR = 1.25, 95% CI = 0.65--2.41, *p* = 0.509) or age (OR = 1.16, 95% CI = 0.95--1.43, *p* = 0.153) was non-significant in patients with CRC ([Table 3](#table3-1758835920937425){ref-type="table"} and [Figure 4](#fig4-1758835920937425){ref-type="fig"}).

###### 

Correlations of systemic immune-inflammation index and clinicopathological characteristics in patients with colorectal cancer.

![](10.1177_1758835920937425-table3)

  Characteristics                                          No. of studies   No. of patients   Effects model   OR (95% CI)         ***p***   Heterogeneity   
  -------------------------------------------------------- ---------------- ----------------- --------------- ------------------- --------- --------------- ---------
  **Sex, male *versus* female**                            8                2529              Fixed           0.95 (0.80--1.13)   0.592     12.4            0.333
  **Tumor differentiation, poor *versus* moderate/well**   7                2427              Fixed           1.60 (1.27--2.02)   \<0.001   32.0            0.184
  **Tumor location, rectum *versus* colon**                6                1166              Fixed           0.76 (0.58--1.03)   0.081     1.0             0.409
  **Distant metastasis, yes *versus* no**                  4                1990              Random          2.27 (1.10--4.67)   0.026     84.5            \<0.001
  **ECOG PS, 1--2 *versus* 0**                             4                702               Fixed           1.98 (1.39--2.84)   \<0.001   0               0.442
  **Lymph node metastasis, yes *versus* no**               3                1721              Random          1.25 (0.65--2.41)   0.509     73.9            0.022
  **Age, years, \>60 *versus* ⩽60**                        3                1725              Fixed           1.16 (0.95--1.43)   0.153     49.5            0.138
  **Tumor size, ⩾5 cm *versus* \<5 cm**                    3                1721              Fixed           1.49 (1.18--1.88)   0.001     7.4             0.340

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; OR, odds ratio

![Forest plots of the relationship between systemic immune-inflammation index and clinical factors in colorectal cancer. (A) Sex (male *versus* female); (B) tumor differentiation (poor *versus* moderate/well); (C) tumor location (rectum *versus* colon); (D) distant metastasis (yes *versus* no); (E) Eastern Cooperative Oncology Group Performance Status (1--2 *versus* 0); (F) lymph node metastasis (yes *versus* no); (G) age (years) (\>60 *versus* ⩽60); (H) tumor size (⩾5 cm *versus* \<5 cm).\
CI, confidence interval; OR, odds ratio](10.1177_1758835920937425-fig4){#fig4-1758835920937425}

Sensitivity analysis {#section16-1758835920937425}
--------------------

We conducted a sensitivity analysis to assess the reliability of pooled HRs of OS and PFS. The overall HR estimates for OS and PFS ([Figure 5](#fig5-1758835920937425){ref-type="fig"}) were not significantly altered upon sequentially omitting each study from the analysis. Thus, the reliability of the results of this meta-analysis was also confirmed by the sensitivity analysis.

![Sensitivity analysis of the effect of systemic immune-inflammation index on (A) overall survival and (B) progression-free survival in colorectal cancer.](10.1177_1758835920937425-fig5){#fig5-1758835920937425}

Publication bias {#section17-1758835920937425}
----------------

Begg's funnel and Egger's tests were used to estimate potential publication bias. As illustrated in [Figure 6](#fig6-1758835920937425){ref-type="fig"}, there was no significant bias in studies on SII with respect to OS (Begg's *p* = 0.938, Egger's *p* = 0.089) or PFS (Begg's *p* = 0.174, Egger's *p* = 0.733).

![Publication bias tested by Begg's test and Egger's test. (A) Begg's test for overall survival, *p* = 0.938; (B) Egger's test for overall survival, *p* = 0.089; (C) Begg's test for progression-free survival, *p* = 0.174; (D) Egger's test for progression-free survival, *p* = 0.733.](10.1177_1758835920937425-fig6){#fig6-1758835920937425}
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To the best of our knowledge, this study is the first meta-analysis exploring the prognostic and clinicopathological impact of SII in patients with CRC. As a novel prognostic parameter, SII can be easily calculated from routine complete blood count tests and reflects the overall status of the immune systems of cancer patients. Previous investigations on the prognostic value of SII in CRC yielded controversial results. For the current meta-analysis, we collected data from 12 studies with 3919 patients to clarify the role of SII in CRC prognosis. Significant prognostic efficiency in different subgroups suggests that high SII was a robust prognostic marker for long-term survival outcomes, including the OS and PFS. Moreover, high SII prior to treatment was related to poor tumor differentiation, presence of distant metastasis, ECOG PS of 1--2 and tumor size of ⩾5 cm. Considering these clinical parameters related to the invasiveness and aggressiveness of malignant tumors, high SII could be a potential marker of disease progression and tumor recurrence possibility. The results of our comprehensive and aggregated analysis demonstrate the effectiveness of SII as an index for CRC prognosis.

The tumor microenvironment has recently attracted increasing attention in the field of cancer immunology. Various inflammatory cells and mediators are important components of the tumor microenvironment.^[@bibr24-1758835920937425]^ SII is based on peripheral lymphocyte, neutrophil and platelet counts. A high SII corresponds to high platelet/neutrophil and (or) low lymphocyte counts. Therefore, an elevated SII indicates a highly-inflammatory tumor microenvironment with infiltrating immune cells.^[@bibr25-1758835920937425]^ The presence of neutrophils in the peripheral blood is generally associated with poor prognosis in patients with cancer.^[@bibr26-1758835920937425]^ Neutrophils can activate endothelial and parenchymal cells and thereby facilitate the metastasis of circulating tumor cells (CTCs).^[@bibr27-1758835920937425]^ Neutrophils also mediate the proliferation and metastasis of cancer cells by secreting inflammatory mediators.^[@bibr28-1758835920937425]^ Moreover, platelets may shield CTCs to protect them from antitumor immune responses, and therefore promote angiogenesis and metastasis of cancer cells.^[@bibr29-1758835920937425]^ Platelets also release a variety of growth factors that enhance cancer cell proliferation *in vitro*.^[@bibr30-1758835920937425]^ Lymphocytes, especially tumor-infiltrating lymphocytes, further play a pivotal role in the host immune response to malignancy.^[@bibr31-1758835920937425]^ Lymphocytes can induce cytotoxic cell death and inhibit tumor cell proliferation and migration.^[@bibr32-1758835920937425]^ Therefore, SII may also reflect the activation of inflammatory and immune pathways in the host. In addition, the measurements required for the calculation of SII are inexpensive, easily-performed and reproducible, rendering SII a promising marker for CRC prognosis in clinical practice.

The prognostic role of SII in solid tumors has also been investigated in several meta-analyses previously.^[@bibr33-1758835920937425],[@bibr34-1758835920937425]^ A meta-analysis focusing on the use of SII in multiple cancers showed that high SII was associated with poor OS.^[@bibr33-1758835920937425]^ A meta-analysis of data from 2786 lung cancer patients based on seven studies indicated that SII prior to treatment was a prognostic factor for OS.^[@bibr35-1758835920937425]^ Another recent retrospective study showed that baseline SII could serve as an independent prognostic marker for patients with advanced pancreatic cancer.^[@bibr36-1758835920937425]^ The SII was also suggested as a novel independent prognostic factor for predicting OS and PFS in patients with classical Hodgkin lymphoma.^[@bibr37-1758835920937425]^ Here, we demonstrated the prognostic efficiency of SII with respect to OS and PFS in CRC, in line with the findings on other cancer types. In addition, we also demonstrated correlations between high SII and clinical parameters in CRC. Based on our findings and other relevant studies, SII may assist in the cancer prognosis and help develop clinical treatment strategies. For example, hepatocellular carcinoma patients with high SII prior to treatment may benefit more from neoadjuvant chemoradiotherapy, postoperative adjuvant chemoradiotherapy and other cancer-related therapies than patients with low SII.^[@bibr38-1758835920937425]^ SII has also shown good prognostic efficiency in multiple cancers,^[@bibr33-1758835920937425],[@bibr34-1758835920937425]^ which suggests that elevated SII may be a general feature in solid tumors. However, the prognostic value of SII for hematological and other types of cancer, such as gynecological tumors, remains to be investigated. Further investigations focusing on the prognostic impact of SII on diverse cancer types are needed to justify the application of SII in the clinical management of patients with cancer.

Although this study is the first meta-analysis on SII and CRC prognosis to date, there are also several limitations. First, most of the included studies were of retrospective design, which hindered controlling the selection criteria and led to heterogeneity among studies. Second, several HRs were extracted from univariate analyses, and may eventually overestimate effect sizes. Univariate analysis was performed without consideration of confounding factors. Third, SII cut-off values as well as determination methods are not uniform in the included studies, which could cause bias in the results.

In summary, this meta-analysis indicated that higher SII before treatment was correlated with poor OS and PFS in patients with CRC. In addition, high SII was associated with clinical factors implying higher malignancy of the disease. We conclude that SII may play an important role in improving clinical decision-making for CRC. However, larger-scale prospective studies are still needed to validate our results due to the limitations of this study.
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